ApolipoproteinA‐I: Insights from redox proteomics for its role in neurodegeneration
- 2 October 2012
- journal article
- review article
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 7 (1-2) , 109-122
Abstract
Proteomics has a wide range of applications, including determination of differences in the proteome in terms of expression and post‐translational protein modifications. Redox proteomics allows the identification of specific targets of protein oxidation in a biological sample. Using proteomic techniques, apolipoproteinA‐I(ApoA‐I) has been found at decreased levels in subjects with a variety of neurodegenerative disorders including in the serum and cerebrospinal fluid (CSF) ofAlzheimer disease (AD),Parkinson disease (PD), andDown syndrome (DS) with gout subjects.ApoA‐Iplays roles in cholesterol transport and regulation of inflammation. Redox proteomics further showedApoA‐Ito be highly oxidatively modified and particularly susceptible to modification by 4‐hydroxy‐2‐trans‐nonenal (HNE), a lipid peroxidation product. In the current review, we discuss the consequences of oxidation ofApoA‐Iin terms of neurodegeneration.ROS‐associated chemotherapy relatedApoA‐Ioxidation leads to elevation of peripheral levels of tumor necrosis factor‐α (TNF‐α) that can cross the blood‐brain barrier (BBB) causing a signaling cascade that can contribute to neuronal death, likely a contributor to what patients refer to as “chemobrain.” Current evidence suggestsApoA‐Ito be a promising diagnostic marker as well as a potential target for therapeutic strategies in these neurodegenerative disorders.Keywords
This publication has 148 references indexed in Scilit:
- Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndromeBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disordersPharmacological Research, 2011
- Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of actionPharmacological Research, 2011
- Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease☆Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2008
- Identification of Proteins Adducted by Lipid Peroxidation Products in Plasma and Modifications of Apolipoprotein A1 with a Novel Biotinylated Phospholipid ProbeJournal of Proteome Research, 2008
- Tumor necrosis factor alpha–mediated nitric oxide production enhances manganese superoxide dismutase nitration and mitochondrial dysfunction in primary neurons: an insight into the role of glial cellsNeuroscience, 2008
- Protein Damage by Reactive Electrophiles: Targets and ConsequencesChemical Research in Toxicology, 2007
- Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairmentFree Radical Biology and Medicine, 2007
- Oxidative stress in Parkinson's diseaseAnnals of Neurology, 2003